Valspodar
As of the edition of 20 October 2026, Valspodar is a protein: went quiet in 2010; acts on ABCB1.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Went quiet, 2010
- Kind
- Protein
- Registered trials
- 13, 0 stopped early
- Disease areas
- Cancer; Blood and lymph; Immune system; Skin and connective tissue; Inherited and neonatal; Pregnancy and women's health
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| ABCB1 | ATP-dependent translocase ABCB1 | P08183 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 5 | 5 | 0 | 0 |
| Phase 2 | 4 | 4 | 0 | 0 |
| Phase 3 | 4 | 4 | 0 | 0 |
| All trials | 13 |